Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18474236 | 0.78 | PGR (0.45) | KMT2ASLC5A1SLC5A2PGRKDM1A | |
| SCHEMBL17193998 | 0.75 | SLC5A1 (0.37) | KMT2ASLC5A1SLC5A2PGRKDM1A | |
| SCHEMBL18469490 | 0.72 | KMT2A (0.34) | KMT2ASIGMAR1SLC5A1SLC5A2PGR | |
| SCHEMBL17193999 | 0.69 | PGR (0.44) | SIGMAR1PGRALDH1A1 | |
| SCHEMBL12964402 | 0.69 | OPRL1 (0.45) | SIGMAR1OPRL1 | |
| SCHEMBL20031039 | 0.68 | HTR1D (0.38) | — | |
| SCHEMBL12691802 | 0.66 | ADRA2A (0.40) | SIGMAR1PGRALDH1A1 | |
| SCHEMBL24151285 | 0.66 | AKR1B1 (0.37) | AKR1B1ALDH1A1 | |
| SCHEMBL19810463 | 0.66 | KDM1A (0.36) | KMT2AHTR5AKDM1AIDO1AKR1B1 | |
| SCHEMBL19810469 | 0.66 | AKR1B1 (0.37) | KDM1AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | KMT2A 873/4885SIGMAR1 3164/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.